Search | Page 16 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Scientific Symposium Co-Chair Richard Stone, MD Discusses Progress and New Directions in Bone Marrow Failure Disease Research

    ... report at the meeting from Dr. Benjamin Ebert about how lenalidomide might work to effect on ubiquitin ligase and the ability to ...

    Interview last updated 04/29/2014 - 12:01pm.

  2. Research Overview - Recent Past Progress and Projections for the Near-Term

    ... that takes you back to further science basic research. Lenalidomide is a good example of this. In the laboratory, we saw it ... to find out what are the targets in deletion 5q that allowed lenalidomide to suppress the clone. Later, as patients failed lenalidomide, we ...

    Interview last updated 02/10/2014 - 9:40am.

  3. Research Overview – Recent Past Progress and Projections for the Near-Term

    ... have a discovery that takes you back to basic research.  Lenalidomide is a good example of this –in the laboratory we saw it affected ... to suppress the clone. Then when patients failed lenalidomide , we went back and studied the mechanism for resistance to the ...

    Page last updated 01/14/2014 - 11:47am.

  4. A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)

    ... Associated Drug(s):  Lenalidomide Phase:  ... infusion Other Names: MK-3475 KEYTRUDA® Drug: Lenalidomide oral capsules Other Name: REVLIMID® ...

    Clinical Trial last updated 04/28/2016 - 10:54am.

  5. What MDS Patients Should Know About Clinical Trials

    ... approved drugs available for people with MDS. These are lenalidomide (Revlimid®), azacitidine (Vidaza®), and ... MDS -- received either azacitidine alone, azacitidine and lenalidomide, or azacitidine combined with vorinostat.  I wrote this study ...

    Interview last updated 11/13/2015 - 11:12am.

  6. Interviews with the Experts Managing MDS With Supportive Care and Active Treatment

    ... agent in this group that also improves blood counts is lenalidomide (Revlimid®), but it has a different mechanism of action from ... agents and is categorized as an immunomodulatory agent. Lenalidomide has been shown to be best suited for a subset of MDS patients ...

    Interview last updated 09/22/2014 - 12:25pm.

  7. Interviews with the Experts Comorbidities: When Other Medical Conditions Affect MDS Treatment

    ... on dialysis, it’s very difficult to know what dose of lenalidomide (Revlimid®) to give them because this drug is eliminated via ... with standard therapies such as azacitidine (Vidaza®) or lenalidomide (Revlimid®). The more things that are wrong with a patient, the ...

    Interview last updated 11/17/2014 - 9:31am.

  8. Clinical Trial Basics

    ... decitabine (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) eculizumab (Soliris) azacitidine ...

    Page last updated 01/20/2015 - 4:58pm.

  9. Clinical Trial Basics

    ... decitabine (Dacogen) deferasirox (Exjade) lenalidomide (Revlimid) eculizumab (Soliris) azacitidine ...

    Page last updated 01/20/2015 - 4:46pm.

  10. Lower-Risk MDS: Diagnosis and Treatment Options

    ... have a very good chance of responding to a drug called lenalidomide (Revlimid®), with about a 75% chance of becoming ... they have been needing red blood cell transfusions. Lenalidomide is a pill that is usually taken every day. If a lower-risk ...

    Interview last updated 05/18/2012 - 1:28pm.